FANIN, RENATO
 Distribuzione geografica
Continente #
NA - Nord America 3.258
EU - Europa 693
AS - Asia 468
AF - Africa 9
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.438
Nazione #
US - Stati Uniti d'America 3.251
SE - Svezia 423
HK - Hong Kong 244
CN - Cina 170
BG - Bulgaria 83
IE - Irlanda 81
IT - Italia 39
KR - Corea 27
DE - Germania 20
BE - Belgio 15
IN - India 9
SN - Senegal 8
CA - Canada 7
FI - Finlandia 7
TR - Turchia 7
UA - Ucraina 7
CH - Svizzera 6
BR - Brasile 4
AT - Austria 3
GB - Regno Unito 3
SG - Singapore 3
TW - Taiwan 3
CL - Cile 2
CZ - Repubblica Ceca 2
JP - Giappone 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
ES - Italia 1
ID - Indonesia 1
IL - Israele 1
PH - Filippine 1
PL - Polonia 1
RO - Romania 1
RU - Federazione Russa 1
TN - Tunisia 1
Totale 4.438
Città #
Fairfield 615
Ashburn 332
Woodbridge 277
Chandler 257
Hong Kong 244
Wilmington 241
Houston 236
Seattle 236
Cambridge 207
Princeton 166
Ann Arbor 137
Beijing 87
Jacksonville 85
Sofia 83
Dublin 81
Boardman 68
San Diego 44
Seoul 27
Brussels 15
Trieste 14
Norwalk 13
Washington 10
Bremen 9
Dakar 8
Andover 7
Monmouth Junction 7
Bern 6
Fremont 6
Nanjing 6
Pune 6
Toronto 6
Helsinki 5
Kocaeli 5
Shanghai 4
Augusta 3
Casier 3
Hebei 3
Hefei 3
Kunming 3
Redwood City 3
Shenyang 3
Tianjin 3
Vienna 3
Brno 2
Fuzhou 2
Guangzhou 2
Haikou 2
Jinan 2
Lappeenranta 2
Leawood 2
Lima 2
Mumbai 2
Naples 2
Padova 2
Redmond 2
San Jose 2
San Mateo 2
São Paulo 2
Taiyuan 2
Tappahannock 2
Albuquerque 1
Binangonan 1
Buffalo 1
Castro Valley 1
Changchun 1
Chongqing 1
Dearborn 1
Galati 1
Guaratingueta 1
Haifa 1
Hanover 1
Istanbul 1
Itabashi-ku 1
Izmir 1
Jakarta 1
Lanzhou 1
Lestizza 1
London 1
Milan 1
Nanchang 1
Nicosia 1
Ningbo 1
Nottingham 1
Palo Alto 1
Piemonte 1
Polska 1
Québec 1
Rome 1
Santiago 1
Schio 1
Sebring 1
Singapore 1
Temù 1
Tokyo 1
Wenzhou 1
Yinchuan 1
Zhengzhou 1
Totale 3.648
Nome #
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 106
Rituximab for the treatment of type II mixed cryoglobulinemia 105
Low-dose rituximab in adult patients with primary immune thrombocytopenia 97
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice 89
Bendamustine salvage therapy for T cell neoplasms 87
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 87
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 86
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion 86
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 84
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 83
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 83
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 82
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response 81
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia 79
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab 77
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters 76
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 76
Rituximab in a case of cold agglutinin disease 75
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 75
Management of immune thrombocytopenia in elderly patients 75
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 74
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 73
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 72
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 70
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 69
Paraneoplastic cerebellar degeneration associated with anti-neuronal anti-Tr antibodies in a patient with Hodgkin's disease 68
Meningeal and cerebral involvement in multiple myeloma patients 68
The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma 68
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 67
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 65
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment 65
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 64
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 62
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 62
CD38, BCL-2, PD-1 and PD-1L expression in nodal peripheral T-cell lymphoma (PTCL): Possible biomarkers for novel targeted therapies? 61
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 60
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 60
Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia 60
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma 60
The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease 59
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients 59
Treatment of refractory chronic GVHD with rituximab: a GITMO study 58
The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center 57
Hepatitis C virus infection (and additional neoplasms) among marginal zone lymphomas 56
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 56
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 56
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 54
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia 53
Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults 53
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 51
Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: Results of a retrospective, observational GIMEMA study 49
Computed tomography, magnetic resonance and gallium 67 scintigraphy for the imaging of residual lymphoma 48
Prevalence of Hepatitis C Virus infection in patients with lymphoproliferative disorder 47
Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation 46
B-cell compartment as the selective target for the treatment of immune thrombocytopenias 46
Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammapathy of undetermined significance 46
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma 45
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 45
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas 43
Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas 41
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 39
No evidence for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy” 39
Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome 38
Risk of C virus infection in Waldenstrom’s syndromes and monoclonal gammopathies 38
The role of Rituximab in the therapy of mixed cryoglobulinemia 37
Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome 37
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers 36
High-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's lymphoma: a single center experience 35
High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome 34
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies 34
Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation 34
Predicting lymphoma in Sjögren's syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording 32
Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome 32
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas 31
Hepatitis C virus and lymphoproliferative disorders 30
Myasthenia gravis after allogeneic bone marrow transplantation: a case report 27
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study 25
Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine 25
The F-MACHOP regimen in the treatment of aggressive non-Hodgkin’s lymphomas: a single centre experience in 72 patients 23
Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha 22
Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma 20
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 20
Myasthenia gravis after allogeneic bone marrow transplantation. A case report and a review of the literature 19
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab 18
Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients 18
Totale 4.748
Categoria #
all - tutte 17.966
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.966


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201912 0 0 0 0 0 0 0 0 0 2 6 4
2019/20201.126 2 1 1 4 90 195 248 195 200 86 51 53
2020/20211.093 57 136 113 103 82 127 22 89 15 102 66 181
2021/2022937 17 106 2 131 4 23 49 32 113 73 38 349
2022/2023971 117 127 102 60 101 191 1 104 114 17 32 5
2023/2024607 28 29 69 15 33 94 122 181 30 6 0 0
Totale 4.748